Literature DB >> 10710290

Identification of an interaction between the angiotensin II receptor sub-type AT2 and the ErbB3 receptor, a member of the epidermal growth factor receptor family.

D Knowle1, S Ahmed, L Pulakat.   

Abstract

To identify the proteins that interact and mediate angiotensin II receptor AT2-specific signaling, a random peptide library was screened by yeast-based Two-Hybrid protein-protein interaction assay technique. A peptide that shared significant homology with the amino acids located between the residues Gly-Xaa-Gly-Xaa-Xaa-Gly721 and Lys742, the residues predicted to be important for ATP binding of the ErbB3 and ErbB2 receptors, was identified to be interacting with the AT2 receptor. The interaction between the human ErbB3 receptor and the AT2 receptor was further confirmed using the cytoplasmic domain (amino acids 671-782) of the human ErbB3 receptor. Moreover, an AT2 receptor peptide that spans the amino acids 226-363, (spans the third ICL and carboxy terminal domain) could also interact with the AT2 receptor in a yeast Two-Hybrid protein-protein interaction assay. Studies using mutated and chimeric AT2 receptors showed that replacing the third intracellular loop (ICL) of the AT2 receptor with that of the AT1 abolishes the interaction between the ErbB3 and the AT2 in yeast Two-Hybrid protein-protein interaction assay. Thus the interaction between the AT2 receptor and the ErbB3 receptor seems to require the region spanning the third ICL and carboxy terminus of the AT2 receptor. Since the third ICL of the AT2 receptor is essential for exerting its inhibitory effects on cell growth, possible involvement of this region in the interaction with the cytoplasmic domain of the ErbB3 receptor suggests a novel signaling mechanism for the AT2 receptor mediated inhibition of cell growth. Furthermore, since both the AT2 and the ErbB3 receptors are expressed during fetal development, we propose that the existence of direct interaction between these two receptors may play a role in the regulation of growth during the initial stages of development.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10710290     DOI: 10.1016/s0167-0115(99)00111-1

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  10 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 2.  Angiotensin receptor-associated proteins: local modulators of the renin-angiotensin system.

Authors:  Hayo Castrop
Journal:  Pflugers Arch       Date:  2012-05-16       Impact factor: 3.657

Review 3.  Cardiac GPCR-Mediated EGFR Transactivation: Impact and Therapeutic Implications.

Authors:  Laurel A Grisanti; Shuchi Guo; Douglas G Tilley
Journal:  J Cardiovasc Pharmacol       Date:  2017-07       Impact factor: 3.105

Review 4.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

5.  Novel Pharmacology Following Heteromerization of the Angiotensin II Type 2 Receptor and the Bradykinin Type 2 Receptor.

Authors:  Elizabeth K M Johnstone; Mohammed Akli Ayoub; Rebecca J Hertzman; Heng B See; Rekhati S Abhayawardana; Ruth M Seeber; Kevin D G Pfleger
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-26       Impact factor: 6.055

6.  Pre-miRNA Hsa-Let-7a-2: a Novel Intracellular Partner of Angiotensin II Type 2 Receptor Negatively Regulating its Signals.

Authors:  Xiaoyan Liu; Zhenzhen Chen; Shuangyue Li; Ling Jin; Xiao Cui; Changting Cui; Yue Deng; Qiannan Gao; Luyun Fan; Yaping Niu; Wenjie Wang; Chunmei Cui; Jiuchang Zhong; Qinghua Cui; Bin Geng; Jun Cai
Journal:  Int J Biol Sci       Date:  2022-05-01       Impact factor: 10.750

Review 7.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

8.  Candidate Agtr2 influenced genes and pathways identified by expression profiling in the developing brain of Agtr2(-/y) mice.

Authors:  Traci L Pawlowski; Silvia Heringer-Walther; Chun-Huai Cheng; John G Archie; Chin-Fu Chen; Thomas Walther; Anand K Srivastava
Journal:  Genomics       Date:  2009-06-06       Impact factor: 5.736

9.  Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism.

Authors:  Lingaku Lee; Irene Ramos-Alvarez; Terry W Moody; Samuel A Mantey; Robert T Jensen
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2019-12-17       Impact factor: 4.739

10.  Oncogenic miR-19a and miR-19b co-regulate tumor suppressor MTUS1 to promote cell proliferation and migration in lung cancer.

Authors:  Yuanyuan Gu; Shuoxin Liu; Xiaodan Zhang; Guimin Chen; Hongwei Liang; Mengchao Yu; Zhicong Liao; Yong Zhou; Chen-Yu Zhang; Tao Wang; Chen Wang; Junfeng Zhang; Xi Chen
Journal:  Protein Cell       Date:  2017-03-31       Impact factor: 14.870

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.